Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On July 31, 2025, Soligenix, Inc. (SNGX) announced encouraging results from the Phase 2a clinical trial of SGX-945 (dusquetide) for the treatment of Behcet's disease (BD) in which the compound demonstrated biological efficacy.</li><li>This was an open-label study designed to be highly comparable to the Phase 3 trial of apremilast (Otezla ) that was the basis for marketing approval for oral ulcers in BD.</li><li>Using the same primary endpoint as the Phase 3 apremilast study (area under the curve of the mean number of ulcers vs. time), after four weeks of treatment the SGX945 group had a 40% improvement relative to the placebo group from the Phase 3 apremilast study, while apremilast had a 37% improvement relative to placebo.</li></ul>

On July 31, 2025, Soligenix, Inc. (SNGX) announced encouraging results from the Phase 2a clinical trial of SGX-945 (dusquetide) for the treatment of Behcet's disease (BD) in which the compound demonstrated biological efficacy.This was an open-label study designed to be highly comparable to the Phase 3 trial of apremilast (Otezla ) that was the basis for marketing approval for oral ulcers in BD.Using the same primary endpoint as the Phase 3 apremilast study (area under the curve of the mean number of ulcers vs. time), after four weeks of treatment the SGX945 group had a 40% improvement relative to the placebo group from the Phase 3 apremilast study, while apremilast had a 37% improvement relative to placebo.

SNGX: 베체트병에 대한 SGX945의 2a상 연구에서 긍정적인 결과 도출 